FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

OMB APPROVAL

OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5

	Check this box if no longer subject to
١	Section 16. Form 4 or Form 5
ı	obligations may continue. See
	Instruction 1(b)

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* MARTELL RON					2. Issuer Name and Ticker or Trading Symbol Jasper Therapeutics, Inc. [JSPR]									Relationship of Reporting Person(s) to Issuer (Check all applicable) X Director 10% Owner					
(Last) (First) (Middle)														X Officer below)	Officer (give title below)			pecify	
C/O JASPER THERAPEUTICS, INC. 2200 BRIDGE PKWY, SUITE 102					3. Date of Earliest Transaction (Month/Day/Year) 02/02/2023									President, CEO & Director					
(Street) REDWO	OD C	A	94065		4. If Amendment, Date of Original Filed (Month/Day/Year)								6. I	Individual or Joint/Group Filing (Check Applicable Line) X Form filed by One Reporting Person Form filed by More than One Reporting Person					
(City)	(S	tate)	(Zip)																
	Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned																		
1. Title of Security (Instr. 3) 2. Trans: Date (Month/I				te	action 2A. Deemed Execution Date if any (Month/Day/Yea			Code (Instr.				red (A) or str. 3, 4 and	5. Amour Securitie Beneficia Owned F Reported	Form (D) or		Direct Indirect Etr. 4)	7. Nature of ndirect Beneficial Dwnership Instr. 4)		
								Cod	e V	Amo	ount	(A) or (D)		Transacti (Instr. 3 a			"	nsu. 4)	
	Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)																		
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code (Instr.		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)			_ i	Securities	d Amount o s Underlying e Security nd 4)		derivativ Securiti Benefici Owned Followir Reporte	ve es ially ng	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)	
	Code V (A) (D)						(D)	Date Exercis	able	Expirat Date		Title	Amount o Number o Shares		Transac (Instr. 4)				
Stock Option (right to buy)	\$1.78	02/02/2023		A		1,093,831		(1)		02/02/2	2033	Voting Common Stock	1,093,83	\$0.00	1,093	,831	D		

Explanation of Responses:

1. 1/4th of the shares subject to the option shall vest on February 2, 2024, and 1/48th of the shares subject to the option shall vest following each one-month period thereafter, subject to the Reporting Person's continuous service to the Issuer on and through each applicable vesting date, inclusive.

/s/ Ronald A. Martell

02/03/2023

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.